Status:
ENROLLING_BY_INVITATION
Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria
Lead Sponsor:
French Society for Intensive Care
Collaborating Sponsors:
SPILF
Conditions:
Critical Care
Infection
Eligibility:
All Genders
Brief Summary
The AZAVI study is a multicenter observational registry (ICU and Infectious Diseases departments), designed to evaluate the real-world use of aztreonam-avibactam for suspected or documented infections...
Detailed Description
1. Background and Rationale The emergence of carbapenemase-producing bacteria, particularly metallo-β-lactamase (MBL) producers such as NDM, poses a major therapeutic challenge in intensive care setti...
Eligibility Criteria
Inclusion
- Hospitalized patients with suspected or documented infection due to MBL-producing bacteria, treated with ATM-AVI.
Exclusion
- Explicit refusal by patient or legal representative.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07176247
Start Date
January 1 2024
End Date
December 31 2028
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
French Society of Intensive Care (SRLF)
Paris, France